Collegium Pharmaceutical, Inc. Debt Instrument, Fair Value Disclosure
Collegium Pharmaceutical, Inc. (COLL) had Debt Instrument, Fair Value Disclosure of $458.33 million as of 2023-09-30, per its 10-Q filed 2023-11-07.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2023-11-07
- 2023-09-30: Debt Instrument, Fair Value Disclosure $458.33M.
- 2023-06-30: Debt Instrument, Fair Value Disclosure $504.17M.
- 2023-03-31: Debt Instrument, Fair Value Disclosure $550.00M.
- 2022-09-30: Debt Instrument, Fair Value Disclosure $600.00M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2023-09-30 | $458.33M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $504.17M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $550.00M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $600.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $625.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $650.00M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |